NASDAQ$OKUR
OnKure Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
OnKure Therapeutics reported Q3 2025, net loss of $14.7M.
For Q3 2025, OnKure Therapeutics reported a net loss of $14.7M. Management discusses segment performance, capital allocation, and outlook in the earnings filing.
- Net loss $14.7M.
- OnKure Therapeutics highlights liquidity, operations, and near-term priorities.
- OnKure Therapeutics highlights liquidity, operations, and near-term priorities.
Headline financials
Revenue & EPS history
Reneo Pharmaceuticals · Revenue · Quarterly
$804K
Forward guidance
The filing discusses OnKure Therapeutics's outlook for upcoming periods, including capital allocation, operating priorities, and market risks disclosed in the quarterly report.
Tailwinds
- OnKure Therapeutics cites operational execution and demand trends supporting the outlook.
- Balance sheet and liquidity actions aim to fund growth and returns.
Headwinds
- GAAP profitability remained under pressure in Q3 2025.
- Macro, pricing, and input-cost volatility could pressure margins.
- Segment mix and one-time items may affect quarter-to-quarter comparability.
- Clinical trial timing and R&D spend will drive cash needs before product revenue scales.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+2.2%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+3.6%
Avg return
30 days after
52%
11 / 21 earnings
Positive
+21.2%
Q2 2025
Best reaction
-10.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.7% | -15.0% | -6.3% | |
| Q3 2025 | -5.5% | -2.5% | -3.2% | |
| Q2 2025 | +21.2% | +24.6% | +20.2% | |
| Q1 2025 | +12.5% | +7.5% | +21.0% | |
| Q4 2024 | +3.7% | +4.8% | -40.0% | |
| Q3 2024 | +3.2% | +1.8% | -16.7% | |
| Q2 2024 | +9.7% | +15.7% | +5.2% | |
| Q1 2024 | +2.4% | +3.0% | +0.6% | |
| Q4 2023 | +3.0% | +3.6% | +1.2% | |
| Q3 2023 | -0.9% | +5.6% | +21.1% | |
| Q2 2023 | -6.3% | -15.1% | +7.1% | |
| Q1 2023 | -1.4% | -0.9% | +79.3% | |
| Q4 2022 | -10.3% | -1.0% | +65.1% | |
| Q3 2022 | -3.0% | -8.6% | -35.4% | |
| Q2 2022 | -3.0% | +4.1% | +34.6% | |
| Q1 2022 | -5.9% | -10.8% | -28.2% | |
| Q4 2021 | -1.4% | -6.8% | -34.7% | |
| Q3 2021 | +14.8% | +5.7% | -13.2% | |
| Q2 2021 | +0.1% | -3.2% | +2.0% | |
| Q4 2020 | +7.5% | +2.9% | -2.3% | |
| Q1 2021 | +7.5% | +2.9% | -2.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro